MSACL 2018 US Abstract

Topic: Practical Training

Clinical Mass Spectrometry: Benefits and Considerations

Jeff Young (Presenter)
Providence Health And Services

Bio: Jeff Young has been a medical laboratory scientist since 2004. He holds BS degrees in Microbiology and Clinical Laboratory Science. His laboratory career began performing viral pathogen screening on donor blood units at the American Red Cross. He then transitioned to the roles of generalist and technical supervisor at a rural critical access hospital. Later, he worked for an instrument manufacturer as a technical applications specialist focusing on clinical chemistry, immunoassay, and laboratory automation. In his current role, he designs and implements new testing for Providence Regional Laboratory, a core testing facility serving 8 hospitals and multiple clinics throughout Oregon. He has worked with LC-MS/MS for the past 3 years and provides technologist-level insight on building a mass spectrometry bench from the ground up.

Authorship: Jeff Young
Providence Regional Laboratory

Short Abstract

Implementation of liquid chromatography tandem mass spectrometry (LC-MS/MS) testing in a clinical laboratory is major undertaking. This presentation will focus on the operational benefits and drawbacks of performing LC-MS/MS testing. It will compare traditional immunoassay testing to LC-MS/MS and will include discussion on validation, costs, and staffing.

Long Abstract

Introduction

Implementation of liquid chromatography tandem mass spectrometry (LC-MS/MS) testing in a clinical laboratory is major undertaking. This presentation will focus on the operational benefits and drawbacks of performing LC-MS/MS testing. It will compare traditional immunoassay testing to LC-MS/MS and will include discussion on validation, costs, and staffing.

Methods

Providence Regional Laboratory recognized a need for implementation of LC-MS/MS in the core laboratory. This need was based on financial repatriation of send-out testing but more importantly to provide better turnaround time for patient care. This sentiment is familiar to many laboratories considering new mass spectrometry platforms. Laboratories which are beginning the process of implementing a mass spectrometry platform or evaluating its utility will benefit from this discussion.

Results

In early 2015, Providence Regional Laboratory had no equipment, no methodology, no trained staff and no idea where to begin. Over 3 years, we have acquired 2 mass spectrometers, developed our own clinical methods and trained a staff of 4. Our implementation program has grown the mass spectrometry test menu to 7 clinical assays containing 43 individual compounds. This represents over 15,000 test orders performed annually and over 65,000 discrete test results reported.

Conclusions & Discussion

Following this discussion, participants will be able to:

1) Understand differences between immunoassay and LC-MS/MS testing.

2) Identify potential analyte targets for LC-MS/MS testing.

3) Determine appropriate validation and implementation protocols.

4) Recognize unique development and staffing requirements.


References & Acknowledgements:

N/A


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board MemberyesAACC Clinical Laboratory Scientists Advisory Council
Stockno
Expensesno

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no